Home › Compare › IMRSQ vs RYLD

IMRSQ vs RYLD: Dividend Comparison 2026

IMRSQ yields 20000000.00% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMRSQ wins by $4.875981653489057e+49M in total portfolio value
10 years
IMRSQ
IMRSQ
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full IMRSQ calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — IMRSQ vs RYLD

📍 IMRSQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMRSQRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMRSQ + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IMRSQ pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMRSQ
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, IMRSQ beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMRSQ + RYLD for your $10,000?

IMRSQ: 50%RYLD: 50%
100% RYLD50/50100% IMRSQ
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMRSQ buys
0
RYLD buys
0
No recent congressional trades found for IMRSQ or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMRSQRYLD
Forward yield20000000.00% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.875981653489057e+49M$44.5K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$2,587.35
Total dividends collected$4.875978515990276e+49M$18.8K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IMRSQ vs RYLD ($10,000, DRIP)

YearIMRSQ PortfolioIMRSQ Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$11,914$1,213.65+$2000.00M → IMRSQ
2$373,835,915,712,384$373,833,775,700,934.50$14,099$1,351.30+$373835915.70M → IMRSQ
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$16,580$1,494.55+$65304953364964.95M → IMRSQ
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$19,384$1,642.61+$10661728832755499008.00M → IMRSQ
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$22,535$1,794.70+$1.626767783781495e+24M → IMRSQ
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$26,063$1,950.00+$2.319743300546251e+29M → IMRSQ
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$29,995$2,107.69+$3.0915106403922057e+34M → IMRSQ
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$34,361$2,266.99+$3.8505079858392777e+39M → IMRSQ
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$39,194$2,427.12+$4.4821026103531426e+44M → IMRSQ
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$44,525$2,587.35+$4.875981653489057e+49M → IMRSQ

IMRSQ vs RYLD: Complete Analysis 2026

IMRSQ — Stock

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.

Full IMRSQ Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this IMRSQ vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMRSQ vs SCHDIMRSQ vs JEPIIMRSQ vs OIMRSQ vs KOIMRSQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.